Imatinib shows improved outcomes for patients with severe COVID-19 in the CounterCOVID clinical trial (Cheap cancer drug reduced deaths 45% by addressing pulmonary edema)

Medical Xpress / American Thoracic Society / ATS 2022 international conference ^ | May 18, 2022 | Job R. Schippers, MD et al

[ConservativeMind]

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up.

The study investigated the long-term efficacy of imatinib in hospitalized COVID-19 patients. A tyrosine kinase inhibitor, imatinib is currently an oncology drug as it blocks an abnormal protein that signals cancer cells. The drug also blocks potentially deadly leakage of small blood vessels in the lungs under inflammatory conditions, as seen in severe SARS-CoV-2.

According to Job R. Schippers, MD, "Imatinib was considered as a therapeutic option when it became evident that patients with severe COVID-19 had CT scan abnormalities suggestive of pulmonary edema (a condition in which excess fluid accumulates in the lungs and impairs oxygen uptake) as a result of vascular leakage." The researchers found that in addition to reduced mortality rates at 90 days, critically ill patients required a shorter duration of invasive ventilation and less supplemental oxygen.

The researchers were able to determine clinical outcomes for all 385 patients—both for the imatinib and placebo groups. At day 90, 18 (9.1 percent) patients in the imatinib group and 31 (16.5 percent) patients in the placebo group had died. Patients admitted to the ICU who were treated with imatinib had a median of 84 [54-88] ventilator-free days versus 64 [0-85] in patients treated with a placebo. The median duration of invasive ventilation was 7 [3-15] days in the imatinib group and 12 [6-22] days in the placebo group. The median length of ICU admission was 9 [5-16] days in the imatinib group and 13 [7-21] days in the placebo group. Invasively ventilated patients treated with imatinib had a more favorable course of FiO2 (a measure for the concentration of oxygen that a person inhales).

"We hypothesize that imatinib confers benefit by reducing pulmonary edema in acute respiratory distress syndrome (ARDS)," the authors stated.

[ConservativeMind]

Thus would appear to be a better option than Remdesivir, for serious cases, both in price (as low as $114 via GoodRx) and in efficacy.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List

This potentially high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Now keeping a new list (“Common/Top Issues”) for conditions expected to only concern at least 1% of the population. Ask to be on either the “Common/Top Issues” or “Everything” list.

Please email or private message me if you want on or off of a list and of which list you desire.

[Delta 21]

Have they found anything that works worse at protecting us from the China Flu than the Fauci’s vaccine?

[KittyKares]

Try convincing a doctor to use this.